Surgical Use of Efanoctocog alfa in Hemophilia A Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study observes the perioperative use of efanesoctocog alfa in hemophilia A patients undergoing surgery. It focuses on real-world administration and outcomes to understand how the ultra-long-acting FVIII product performs during surgical procedures. Data will come from clinical practice at a Lyon-area center and involve patients treated with Altuvoct. The aim is to identify practical dosing patterns and safety signals in the surgical setting. The study does not assign interventions but analyzes data from routine care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hemophilia A
* Surgery performed with Altuvoct®
* Patient consent to participate after receiving detailed written information.

Exclusion Criteria:

* Presence of any blood coagulation disorder other than hemophilia A.
* Detectable factor VIII inhibitors.
* Known severe liver disease.
* Known severe kidney disease.
* Known hypersensitivity to Altuvoct® or any of its excipients.
* Participation in another clinical trial (participation in non-interventional studies is not an exclusion criterion).

Where it's running

• Unité d'Hémostase Clinique Centre Régional de Traitement des Hémophiles Centre de Référence de Maladies Hémorragiques Hôpital Cardiologique Louis Pradel
  Bron, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Denecimig (Mim8) for adults with acquired Haemophilia A

  This study tests whether denecimig can be safe and helpful for adults newly diagnosed with acquired Haemophilia A.

  Recruiting Phase 3 Novo Nordisk A/S · Iowa City, Iowa and 82 other locations · NCT07830732

• SCT800 for preventing and treating bleeds in previously untreated severe hemophilia A patients

  This test tries SCT800, a recombinant factor VIII, as regular prevention and to treat bleeds in male patients with severe hemophilia A who haven't had prior factor VIII treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07437404

• Different doses of Inno8 for adults with haemophilia A.

  This trial will test different doses of the experimental medicine Inno8 in adults with haemophilia A to see if it is safe and how the body handles it.

  Recruiting at 25 sites Phase 1 Novo Nordisk A/S · Aurora, Colorado and 32 other locations · NCT07220564

• Evaluating synovitis in adults with haemophilia A

  This study looks at how often adults with hemophilia A experience joint inflammation caused by bleeding and how it affects their joint health.

  Recruiting University Hospital, Bonn · Bonn, North Rhine-Westphalia · NCT06352216

• Evaluating the effectiveness and safety of FVIII concentrates in young haemophilia A patients

  This study is testing how well and safely a new treatment for hemophilia A works in young children who haven't had much treatment before.

  Recruiting at 33 sites Octapharma · Miami, Florida and 58 other locations · NCT03695978

• Survey on the success of individualized treatment for haemophilia A

  This study is testing whether a personalized high-dose treatment can help people with haemophilia A who have developed inhibitors against factor VIII and if certain lab tests can predict how well this treatment will work.

  Recruiting Haemophilia Centre Rhine Main · Frankfurt am Main, Hesse · NCT02207894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.